- Home
- KFS vs ITOS Comparison
KFS vs ITOS Comparison
Compare KFS & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- ITOS
- Stock Information
- Founded
- KFS 1989
- ITOS 2011
- Country
- KFS United States
- ITOS United States
- Employees
- KFS N/A
- ITOS N/A
- Industry
- KFS Property-Casualty Insurers
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KFS Finance
- ITOS Health Care
- Exchange
- KFS Nasdaq
- ITOS Nasdaq
- Market Cap
- KFS 396.0M
- ITOS 381.2M
- IPO Year
- KFS 1996
- ITOS 2020
- Fundamental
- Price
- KFS $14.03
- ITOS $10.11
- Analyst Decision
- KFS
- ITOS Hold
- Analyst Count
- KFS 0
- ITOS 6
- Target Price
- KFS N/A
- ITOS $10.60
- AVG Volume (30 Days)
- KFS 57.5K
- ITOS 1.6M
- Earning Date
- KFS 08-07-2025
- ITOS 08-11-2025
- Dividend Yield
- KFS N/A
- ITOS N/A
- EPS Growth
- KFS N/A
- ITOS N/A
- EPS
- KFS N/A
- ITOS N/A
- Revenue
- KFS $114,710,000.00
- ITOS $35,000,000.00
- Revenue This Year
- KFS N/A
- ITOS N/A
- Revenue Next Year
- KFS N/A
- ITOS N/A
- P/E Ratio
- KFS N/A
- ITOS N/A
- Revenue Growth
- KFS 6.75
- ITOS 177.89
- 52 Week Low
- KFS $7.06
- ITOS $4.80
- 52 Week High
- KFS $16.80
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- KFS 49.33
- ITOS 53.82
- Support Level
- KFS $13.30
- ITOS $10.10
- Resistance Level
- KFS $14.75
- ITOS $10.16
- Average True Range (ATR)
- KFS 0.52
- ITOS 0.09
- MACD
- KFS -0.14
- ITOS -0.04
- Stochastic Oscillator
- KFS 45.34
- ITOS 7.69
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.